Manufacturing News of Note—Pact Pharma snags Kite's Tim Moore; Catalent, Minerva hook up

stocks
(Pixabay)

> South San Francisco-based Pact Pharma has enticed Tim Moore from Gilead's Kite Pharma to serve as Pact's president and chief technical officer as it develops TCR-T cell therapies for the eradication of solid tumors. Release 

> Catalent and clinical-stage biotech Minerva Neurosciences have struck a deal for the CDMO to manufacture and package the finished dose form of roluperidone (MIN-101), Minerva’s investigational compound for the treatment of symptoms of schizophrenia. Release 

> Cellectis, a Swiss biotech working on immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), has reached an agreement for Lonza to handle clinical manufacturing. Release

> Novasep has launched Senefill, a unit dedicated to fill-and-finish aseptic commercial operations. It is in Seneffe, Belgium. Release

> Nanoform will conduct an evaluation of its nanoparticle technology across a range of AstraZeneca’s pharmaceutical products. Release

> CapsCanada, which makes vegetarian K-CAPS, is moving its headquarters to a facility in Dania Beach, Florida. Release 

 





 

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.